ArticleFrontiers in endocrinology2025
Associations between high-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and their ratio with metabolic dysfunction-associated steatotic liver disease: a retrospective cohort study.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Non-HDL-to-HDL-cholesterol ratio and metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis.BMC gastroenterology · 2026Pooled it
- Non-HDL-to-HDL cholesterol ratio predicts incident T2DM and CHD in non-alcoholic fatty liver disease: evidence from a large clinical cohort and NHANES.Frontiers in nutrition · 2026Article
- Association Between Non-HDL/HDL Cholesterol Ratio and Urinary Incontinence in US Women:NHANES 2005-2018.International journal of women's health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: High-density lipoprotein cholesterol (HDL-C), non-HDL-C, and the ratio of non-HDL-C to HDL-C (NHHR) are closely correlated with multiple metabolic diseases. This study aims to dissect their associations and differences in relation to new-onset MASLD. Methods: Data were collected from research subjects at the Health Management Center of the Second Affiliated Hospital of Dalian Medical University between 2014 and 2023. Participants were stratified by quartiles of HDL-C, non-HDL-C, and NHHR. Kaplan-Meier analysis, Cox proportional hazards models, restricted cubic splines (RCS), sensitivity analyses, and receiver operating characteristic (ROC) curves were employed to evaluate associations between NHHR, non-HDL-C, HDL-C, and new-onset MASLD and compare predictive performance across lipid parameters. Results: A total of 36,897 participants (mean age 42.1 years; 56.5% female) were followed for a mean of 3.19 years, with 20.3% developing new-onset MASLD. Cox regression showed that compared to the Q1 group, the Q4 group of NHHR and non-HDL-C had a 134% (HR=2.34, 95% CI: 2.13-2.56) and 22% (HR=1.22, 95% CI: 1.13-1.31) higher risk of MASLD, respectively, while HDL-C was associated with a 45% lower risk (HR=0.55, 95% CI: 0.50-0.60). RCS analysis demonstrated nonlinear relationships for NHHR (threshold = 2.54) and HDL-C (threshold = 1.31 mmol/L), whereas non-HDL-C displayed a linear, positive association with MASLD risk. Stratified analyses revealed that elevated non-HDL-C levels conferred higher MASLD risk in men, whereas females, younger adults, and individuals with lower cardiometabolic burden (BMI <24 kg/m², nonhypertensive, and nonhyperuricemic status) showed steeper increases in MASLD risk with rising NHHR quartiles. ROC analysis indicated NHHR was superior to other lipid parameters in predicting MASLD risk. Conclusion: Decreases in HDL-C levels and increases in non-HDL-C and NHHR levels may increase the risk of MASLD. The NHHR can be used as a new index that is stronger than other lipoproteins for the prediction of MASLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.